Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses
Abstract
AIMS: In a phase 2 trial, the efficacy and safety of the highly selective aldosterone synthase inhibitor vicadrostat, alone or with empagliflozin, were investigated in people with chronic kidney disease (CKD) with or without type 2 diabetes (T2D).
MATERIALS AND METHODS: Adults (n = 586) with CKD (estimated glomerular filtration rate [eGFR] 30 to < 90 mL/min/1.73 m2, urine albumin-creatinine ratio [UACR] 200 to < 5000 mg/g) receiving a maximally tolerated dose of renin-angiotensin system inhibitor were randomised to receive vicadrostat (3, 10 or 20 mg) or matching placebo for 14 weeks, with or without background empagliflozin. The primary outcome, effect on albuminuria at 14 weeks, as well as systolic blood pressure (SBP) and eGFR, was assessed by T2D and obesity subgroups (body mass index [BMI]: ≥ 30 vs. < 30 kg/m2) at baseline.
RESULTS: Consistent with overall study results, the largest UACR reductions were observed in 10 and 20 mg dose groups across both subgroup analyses (adjusted mean reduction 30%-51% vs. 37%-46% in the overall study). UACR reductions were consistent in participants with and without T2D (PINTERACTION = 0.53 and 0.40 with/without empagliflozin, respectively) and irrespective of BMI category at baseline (PINTERACTION = 0.35 and 0.44 with/without empagliflozin, respectively). Effects of vicadrostat treatment on reductions in eGFR and SBP were also consistent across T2D and BMI subgroups.
CONCLUSIONS: Effects of vicadrostat with or without empagliflozin on…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 586 participants or records.
Read the paper
Related studies
- Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa
- Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis
- A methodology for assessing deployment trauma and its consequences in OEF/OIF/OND veterans: The TRACTS longitudinal prospective cohort study
- Post‑COVID‑19 Syndrome in Outpatients: a Cohort Study
- Factors Influencing Primary and Secondary Implant Stability—A Retrospective Cohort Study with 582 Implants in 272 Patients
- Electroacupuncture for Painful Diabetic Peripheral Neuropathy: A Multicenter, Randomized, Assessor-Blinded, Controlled Trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.